What is Zacks Research’s Estimate for Omnicell Q2 Earnings?

Omnicell, Inc. (NASDAQ:OMCL) – Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for shares of Omnicell in a report released on Friday, May 8th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.30 per share for the quarter, up from their prior forecast of $0.19. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Omnicell’s current full-year earnings is $1.34 per share. Zacks Research also issued estimates for Omnicell’s Q3 2026 earnings at $0.27 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.27 EPS, Q1 2027 earnings at $0.31 EPS, Q2 2027 earnings at $0.32 EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at $0.37 EPS, FY2027 earnings at $1.34 EPS, Q1 2028 earnings at $0.41 EPS and FY2028 earnings at $1.71 EPS.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to analysts’ expectations of $304.02 million. During the same quarter in the previous year, the business earned $0.26 EPS. Omnicell’s revenue was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS.

A number of other research firms have also recently issued reports on OMCL. Benchmark restated a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Craig Hallum restated a “buy” rating and set a $55.00 price objective on shares of Omnicell in a report on Wednesday, April 29th. KeyCorp boosted their price objective on Omnicell from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, April 28th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a report on Sunday. Finally, Wells Fargo & Company upped their target price on Omnicell from $52.00 to $55.00 and gave the stock an “overweight” rating in a report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Omnicell has an average rating of “Buy” and an average target price of $59.86.

Omnicell Price Performance

OMCL opened at $43.17 on Thursday. The business has a fifty day moving average of $37.54 and a 200 day moving average of $40.23. Omnicell has a 52-week low of $26.84 and a 52-week high of $55.00. The company has a quick ratio of 1.29, a current ratio of 1.50 and a debt-to-equity ratio of 0.13. The stock has a market cap of $1.96 billion, a P/E ratio of 98.12, a PEG ratio of 1.10 and a beta of 0.96.

Institutional Investors Weigh In On Omnicell

A number of hedge funds have recently made changes to their positions in the stock. Cerity Partners LLC lifted its stake in shares of Omnicell by 4.9% during the 4th quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock worth $345,000 after purchasing an additional 354 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Omnicell by 6.6% during the 3rd quarter. SG Americas Securities LLC now owns 6,433 shares of the company’s stock worth $196,000 after purchasing an additional 401 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock worth $1,013,000 after purchasing an additional 424 shares during the last quarter. Martin & Co. Inc. TN increased its position in Omnicell by 0.4% during the 3rd quarter. Martin & Co. Inc. TN now owns 121,720 shares of the company’s stock valued at $3,706,000 after buying an additional 443 shares in the last quarter. Finally, Legal & General Group Plc increased its position in Omnicell by 0.3% during the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after buying an additional 448 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 7,405 shares of the company’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares in the company, valued at $3,355,112.73. This represents a 7.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. 2.92% of the stock is owned by company insiders.

Key Headlines Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks Research increased Omnicell’s FY2026 EPS estimate to $1.27 from $0.87, signaling stronger expected profitability.
• Positive Sentiment: The analyst also raised FY2027 EPS to $1.34 from $1.13 and FY2028 EPS to $1.71 from $1.44, reinforcing a more optimistic long-term outlook.
• Positive Sentiment: Zacks Research maintained a Strong-Buy rating and raised estimates across several quarterly periods, including Q2 2026, Q3 2026, Q4 2026, and 2027 quarters.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.